26 results about "Mouse Macrophage" patented technology

This invention relates to a novel substance with in vitro anti-inflammatory activity, its preparation method, and its application. The chemical name of maltol-3-1'-ethoxyhexane-1”,2”,3”,4”,5”,6”-hexaol-(4'-2”)-glucopyranoside is C. 21 H 34 O 13 Preparation method: 1. Extract *Trollius chinensis* with 70% ethanol (v / v); 2. Concentrate the extract until no alcohol odor remains and load it onto a D101 macroporous resin column; 3. Elute the fraction from the D101 macroporous resin with 30% ethanol, separate by silica gel column chromatography and gel column chromatography, and then obtain *Trollius chinensis* glycoside C using high-performance liquid chromatography. *Trollius chinensis* glycoside C is used to prepare anti-inflammatory drugs. The IC50 of *Trollius chinensis* glycoside C in this invention inhibits the release of pro-inflammatory factors TNF-α and IL-6 from LPS-stimulated mouse macrophages (RAW264.7). 50 The concentrations were 22.8 μmol / L and 31.0 μmol / L, respectively, indicating that it has good in vitro anti-inflammatory activity. This invention belongs to the field of research on effective components of natural drugs.

The invention belongs to the technical field of natural pharmaceutical chemistry, and discloses a flavonoid compound in lomatogonium radiatum as well as a preparation method and application thereof.The flavonoid compound is separated from lomatogonium radiatum of a gentiaceae lomatogonium plant, the medicinal material of lomatogonium radiatum is extracted and concentrated, and the flavonoid compound is obtained. And sequentially carrying out macroporous adsorption resin separation, gel column chromatography separation, medium-low pressure ODS column chromatography separation and semi-preparative high performance liquid chromatography separation. Pharmacological studies show that the compound provided by the invention can effectively inhibit the levels of COX2, IL-6 and TNF-alpha in mouse macrophages RAW246.7 caused by lipopolysaccharide (LPS), which indicates that the compound has obvious anti-inflammatory activity and can be used for preparing anti-inflammatory drugs.

The invention discloses ginseng polysaccharide GP40030-1 as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The ginseng polysaccharide GP40030-1 provided by the invention can obviously promote the proliferation of mouse macrophages RAW264.7 and effectively improve the phagocytic ability of cells, is dose-dependent in a concentration range of 12.5-100 mu g / mL, shows excellent immunomodulatory activity, and has a wide application prospect in the aspect of preparing medicines, functional foods or health products for enhancing immunity.

This invention discloses a series of 1-oxo-2,8-diazacyclic decanone derivatives, their synthesis methods, and applications, belonging to the field of pharmaceutical technology. The applicant's experimental results show that the derivatives of this invention have a good inhibitory effect on the release of NO from lipopolysaccharide-induced mouse RAW 264.7 macrophages, exhibiting good anti-inflammatory activity, and can be used to prepare drugs for treating inflammation.

The invention relates to a C2-quaternary carbon indole-3-ketone compound as well as a preparation method and application thereof, the structure of the compound is shown as a structural general formula (I-1) or (I-2), and the compound is prepared by taking an indole-3-ketone derivative or a 3, 3-gem-difluoroindole derivative as a reaction substrate and carrying out Mannich reaction. According to the present invention, the reaction conditions are mild, the atom economy is high, the highest yield of the synthesized C2-quaternary carbon indole-3-one compound can achieve 86%, and the prepared C2-quaternary carbon indole-3-one compound can inhibit NO released by LPS-induced mouse macrophages RAW264.7, and can be used for preparing drugs for treating NO-mediated inflammatory diseases. Or a product thereof

The present invention contemplates new members of the diprovocim family of compounds that exhibit improvements in both potency and efficacy in the murine system, permitting more effective use in vivo in animal models while maintaining the remarkable activity agonist towards human TLR1 / TLR2. The prototypical new agonist called diprovocim-X exhibits the same excellent potency and efficacy of diprovocim-1 in human THP-1 cells (EC50 of 140 pM vs 110 pM with efficacy 100% that of diprovocim-1 and Pam3CSK4), and displays a superb EC50 of 750 pM in mouse macrophages with an efficacy 550% that of diprovocim-1. Diprovocim-X served as an adjuvant in vivo in mice when co-administrated with a non-immunogenic antigen (OVA), indicating stimulation of the adaptive immune response. These the new diprovocim family compounds are now functionalized for linkage to antigenic, targeting, or delivery moieties, properties to enable precision activation of coordinated innate and adaptive immune responses in target tissues.

The application belongs to the technical field of biology, and discloses a preparation method of a Salmonella typhimurium flagellin and Senecavirus antigen fusion protein. The application selects Escherichia coli Rosetta (DE3) as a host, fuses a Salmonella typhimurium flagellin gene and a Senecavirus antigen gene, optimizes codons, and then clones the fusion protein into a pET-28a (+) vector, so that the obtained fusion protein can keep the adjuvant activity of the flagellin, improve the solubility and expression level of VP2, and the yield can reach 40 mg / L, thereby greatly reducing the expression and purification process cost. The fusion protein provided by the application can activate the TLR5 path and activate mouse macrophages, and the production process is simple and low in cost, so that the application has important significance for the research and production of Senecavirus subunit vaccines.

The invention discloses 1, 4, 11-trioxo-10, 14-diazaspiro decanone as well as a synthesis method and application thereof, and belongs to the technical field of medicines. The test result of the applicant shows that the compound has a good inhibiting effect on NO released by lipopolysaccharide-induced mouse macrophage RAW 264.7, shows good anti-inflammatory activity and can be used for preparing the medicine for treating inflammation.

The invention discloses application of nintedanib in preparation of a medicine for treating plant migration and plant mineralization, and belongs to the technical field of biological medicine. The research shows that the nintedanib has the effects of reducing deposition of extracellular matrix of an allogeneic kidney transplantation model mouse, improving renal tubular atrophy, relieving mouse CD206 + macrophage infiltration and reducing rejection injury degree and immune infiltration degree of kidney grafts after being administered under the administration dosage without generating liver and kidney toxicity and intestinal side effects; the lesion process of mouse chronic transplanted kidney rejection is obviously slowed down, and the damage of excessively activated inflammatory cells to the transplanted kidney is reduced. The results show that nintedanib can delay the progress of chronic transplantation renal fibrosis.

The present invention relates to styraxol derivatives having the structures of Formula (I), Formula (II), or Formula (III), or pharmaceutically acceptable salts thereof. These compounds have excellent anti-inflammatory activity and significantly inhibit the release of nitric oxide (NO), an inflammatory molecule, from mouse macrophages RAW264.7. #imgabs0#

The invention discloses a new application of isopentadecanoic acid, and discloses an application of isopentadecanoic acid in preparation of skin care cosmetics, isopentadecanoic acid has the effects of up-regulating expression of hBD-2 and silk protein in human immortalized keratinocytes, reducing expression synthesis of ROS and TRPV1 in the human immortalized keratinocytes, inhibiting release of NO by mouse macrophages, and inhibiting expression of the human immortalized keratinocytes. And the secretion of sebaceous gland cell grease is reduced.

The invention relates to the technical field of medicinal compounds, and particularly discloses a novel compound (S, E)-5-hydroxy-N-isobutyl-4-oxo-2-decenamide extracted and separated from anacyclus pyrethrum roots, and application of the novel compound in preparation of anti-inflammatory drugs. Modern spectrum technologies such as 1D-NMR (1D-Nuclear Magnetic Resonance), 2D-NMR (2D-Nuclear Magnetic Resonance), high-resolution mass spectrum and the like are used for carrying out structure identification on a monomeric compound obtained through separation, and the molecular structure of the compound is deduced. An enzyme activity experiment result shows that the novel compound has relatively good activity of inhibiting TYK2. Molecular docking results show that the novel compound and the target protein have good binding activity, and the interaction force is mainly hydrogen bonds and hydrophobic force. By detecting the inhibiting effect of the novel compound on the NO release amount of a mouse macrophage line RAW264.7, the novel compound has a good anti-inflammatory effect and has a good application prospect in the aspect of treating inflammation.

The invention discloses a synthetic method and application of antrodia camphorata galactomannan oligosaccharide and polysaccharide, and belongs to the field of carbohydrate chemistry and medicinal chemistry. According to the method, five tetrasaccharide building blocks are used as synthons, the construction efficiency of antrodia camphorata galactose 1, 2-cis-glucosidic bonds is improved through remote participation of galactose 4-position benzoyl, and octasaccharide, hexadecanose and tetracosanose of antrodia camphorata are stereoselectively constructed through [4 + 4], [8 + 8] and [16 + 8] glycosylation strategies by utilizing the method; the obtained oligosaccharides and polysaccharides are subjected to deprotection to obtain six antrodia camphorata galactomannan oligosaccharides and polysaccharides with definite structures, single components and anti-inflammatory activity. A cellular immune experiment shows that the oligosaccharide and the polysaccharide can inhibit LPS (lipopolysaccharide)-induced mouse macrophage RAW 264.7 inflammatory response, and have potential application in anti-inflammatory drugs; meanwhile, the antigens are good antigens of antrodia camphorata sugar vaccines and can be developed into sugar vaccines or sugar drugs.

The application discloses a series of hexa-parallel hexa benzofuran derivatives, a synthesis method and application thereof, and belongs to the technical field of medicines. Test results of the applicant show that part of the target compounds have good inhibitory effect on the release of NO in lipopolysaccharide-induced mouse macrophage RAW 264.7, and can be used for preparing medicines for treating inflammation.

The present invention provides a class of chain polyene vicinal diol compounds and their preparation methods and uses. The inventors obtained compounds Aspertrienediols A and B by separating and purifying the liquid fermentation extract of Antarctic Aspergillus sp.SCSIO 05702. Structural analysis showed that compounds 1 and 2 were both new compounds, and their specific structures were shown in formula (I). Through the evaluation of the anti-inflammatory activity of compounds 1 and 2, it was found that the new compound Aspertrienediol B (2) had a significant inhibitory effect on nitric oxide produced by mouse macrophage cell line RAW264.7 induced by lipopolysaccharide (LPS), and simultaneously inhibited the mRNA expression of pro-inflammatory factors such as MCP-1, IL-6 and TNF-α. At the same concentration, it had no cytotoxic activity on RAW264.7 cells, and could be used as a lead compound for the development of anti-inflammatory drugs.

The application discloses a synthesis method and application of Ganoderma annularis galactomannan oligosaccharide and polysaccharide, and belongs to the field of sugar chemistry and medicinal chemistry. Five tetrasaccharide building blocks are used as synthesis subunits, the construction efficiency of Ganoderma annularis galactose 1,2-cis glycosidic bond is improved through remote participation of benzoyl at the 4th position of galactose, and through [4+4], [8+8] and [16+8] glycosylation strategies, Ganoderma annularis octasaccharide, hexadecasaccharide and twenty-four saccharide are stereoselectively constructed; the obtained oligosaccharide and polysaccharide are deprotected to obtain six Ganoderma annularis galactomannan oligosaccharides and polysaccharides with anti-inflammatory activity, which have definite structures and single components. Through cell immunity experiments, it is found that the above oligosaccharide and polysaccharide can inhibit the inflammatory reaction of LPS-induced mouse macrophage RAW 264.7, has potential application in anti-inflammatory drugs, and is also a good antigen of Ganoderma annularis sugar vaccine, and can be developed into a sugar vaccine or a sugar drug.

The present disclosure is directed to the identification and use of lipids involved in auto-immune reactions and foreign body responses. A. set of phospholipids was observed to preferentially deposit on immune-evasive implants, and these phospholipids upregulated RNA transcripts of anti-inflammatory proteins in murine macrophages. Additionally, a set of fatty acid lipids was observed to preferentially deposit on immunogenic implants, and these fatty acid lipids upregulated RNA transcripts of inflammatory proteins in murine macrophages. Using selected lipids, implantable devices can be engineered to avoid or to attract host immune responses, thereby regulating the length of time the devices are maintained in vivo.

This invention discloses a diphenylheptane compound, a novel chemical component discovered in Alpinia oxyphylla. The invention also identifies the structure of the compound isolated by the above method using physicochemical properties and modern spectroscopic techniques. Furthermore, the invention evaluates the compound's activity using an LPS-induced RAW264.7 cell inflammation model and other activity screening systems, finding that the compound has a certain protective effect on the mouse macrophage line RAW264.7, significantly inhibiting NO release and exhibiting strong anti-inflammatory activity.

The invention belongs to the technical field of medicines, and particularly relates to a novel sesquiterpenoids compound as well as a preparation method and application thereof. The sesquiterpenoids new compound has a structure as shown in a formula (1). The invention provides a novel sesquiterpenoids compound which is extracted and separated from litsea cubeba leaves and has a specific structure, the novel sesquiterpenoids compound has an obvious inhibition effect on the release amount of IL-6 and NO of LPS-induced mouse macrophages RAW264.7, the activity of the novel sesquiterpenoids compound is equivalent to that of a positive control drug dexamethasone, good anti-inflammatory activity is shown, and the novel sesquiterpenoids compound has a good application prospect. The sesquiterpenoids new compound is derived from natural plant components, has small toxic and side effects or is non-toxic, and provides a new thought for developing new anti-inflammatory drugs with smaller side effects and excellent curative effects.

The invention belongs to the field of drugs for inflammatory dermatosis, and discloses an application of myrcene in preparation of drugs for inflammatory dermatosis, which comprises the following steps: combining a mouse AD model (DNCB) with human epidermal keratinocytes (NHEK) and mouse macrophages (RAW264.7); the improvement effect of the MYR is evaluated by adopting histology and immunofluorescence technologies; by integrating transcriptomics and proteomics analysis, the molecular mechanism of MYR for relieving AD symptoms is clarified, and the causal relationship is verified by using a pharmacological inhibitor. The conclusion of the invention is as follows: Myrcene alleviates AD sample inflammation by inhibiting FAK / Src-YAP / TAZ axis. A repeatable mechanism framework is established by the data, and the natural monoterpenoids are associated with biomechanical-nuclear signal transduction and innate immune regulation in AD.

The application relates to a preparation method and application of M1 type macrophages, and the method comprises the following steps: adding activated mouse lymphocytes to a culture system of mouse macrophages for co-culture to obtain M1 type macrophages. The application explores the identification of CD3 / CD28 activated lymphocytes, the influence of activated lymphocytes on the macrophage morphology and the influence of activated lymphocytes on the macrophage subtype, and provides a brand-new method for obtaining mouse M1 type macrophages. The application solves the problem that the stimulation of macrophages by using a recombinant IFN-gamma alone is not enough to completely induce the macrophage polarization. The application provides a new in-vitro mouse M1 type macrophage model for experimental research. The M1 type macrophages induced by the activated lymphocytes can better simulate the immune response process in the body, the required cell state is obtained by using the in-vivo co-culture of two kinds of cells, and compared with the dependence on the exogenous addition of viruses or compounds, the application can effectively avoid many potential risks and disadvantages.

The invention relates to the technical field of microorganisms, and discloses bifidobacterium animalis subsp. Lactis with an effect of relieving colitis and an application of the bifidobacterium animalis subsp. Lactis. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCCNO.33749. The bifidobacterium animalis subsp. Lactis can tolerate an artificial gastrointestinal fluid environment and has a remarkable inhibition capability on intestinal pathogenic bacteria. In a dextran sodium sulfate induced RAW264.7 mouse macrophage inflammation model, the supernate and the cell-free extracting solution can obviously reduce the release of nitric oxide; in a Caco-2 / RAW264.7 cell co-culture inflammation model, the secretion amount of a proinflammatory factor tumor necrosis factor-alpha, interleukin-6 and interleukin-1beta can be remarkably reduced, DSS-induced apoptosis is inhibited, the phagocytic activity of RAW264.7 macrophages is improved, and a new microbial resource is provided for intestinal health maintenance and colitis alleviation.

The present invention discloses an anti-inflammatory composition using a pine cone extract having activity that inhibits NO production in a concentration-dependent manner in mouse macrophage cell lines (RAW 264.7 cells) stimulated with LPS (lipopolysaccharide).

The invention relates to a construction method of a peripheral red blood cell humanized mouse, which comprises the following steps: transplanting human hematopoietic stem cells into the mouse and then applying a red blood cell inducer to the mouse, or applying a red blood cell inducer to the mouse and then infusing human red blood cells into the mouse. The red blood cell inducer comprises an antibody targeting mouse macrophage, dexamethasone or a derivative thereof, and a human macrophage colony stimulating factor. In a mouse transplanted with human hematopoietic stem cells, one or more of an antibody targeting mouse macrophages, dexamethasone and a human macrophage colony stimulating factor can be used in the red blood cell induced maturation process, and high-level human red blood cell reconstruction can be quickly realized within three weeks; the maturity and the denucleation ratio of peripheral human erythrocytes reconstructed in the mouse are completely consistent with those of normal human blood; in a mouse transplanted with human erythrocytes, the erythrocyte induction process can be single treatment of an antibody or dexamethasone, or combined use of the antibody and dexamethasone. The invention also provides application of the peripheral erythrocyte humanized mouse.

The present application relates to the field of biotechnology, in particular to an antibacterial peptide K4 and application thereof.The antibacterial peptide K4 has broad-spectrum antibacterial activity, wherein the MIC of the antibacterial peptide K4 to multi-drug resistant Escherichia coli B2 is 16 μg / mL.Meanwhile, the antibacterial peptide K4 has good thermal stability, enzymatic stability and storage stability, can retain 87.1% of the antibacterial activity after 100 ℃ treatment for 30 min, the antibacterial activity is still higher than 88.7% after protease treatment, retains 91.9% of the antibacterial activity after storage at 4 ℃ for 180 d, and has strong tolerance to strong acidic environment.Furthermore, the hemolysis rate of the antibacterial peptide K4 is less than 4% at an effective antibacterial concentration, and has no obvious toxicity to mouse macrophages.In a multi-drug resistant Escherichia coli B2 infected mouse model, the antibacterial peptide K4 at a dose of 20 mg / kg can increase the survival rate of mice to 90%, and significantly reduce the bacterial load of organs.

The invention belongs to the technical field of pharmacy, and discloses application of physcion in preparation of a medicine for treating fungal keratitis. The invention proposes that the physcion can inhibit the growth of corneal fungi for the first time, and has a treatment effect on fungal keratitis under in-vivo and in-vitro conditions. In an in-vivo experiment, a fungal keratitis model is established by adopting a C57BL / 6 mouse, and the influence of the physcion on the corneal clinical score of the model mouse, the recruitment of macrophages and neutrophils and the expression of NF-kB and interleukin 1beta is researched. In-vitro experiments prove that emodin monomethyl ether with different concentrations has an inhibiting effect on growth of aspergillus fumigatus, and meanwhile, an aspergillus fumigatus stimulated mouse macrophage model verifies the influence of emodin monomethyl ether on an NF-kB / IL-1beta signal channel.